Listed

PharmaCyte Biotech, Inc.: Form 10-K for the period ended Apr 30, 2018

Filed with the SEC on Jul 20, 2018 and accepted by EDGAR at Jul 20, 2018, 17:08 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-04-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2017-05-01 to 2018-04-30$0us-gaap:Revenues
Research and development12 months2017-05-01 to 2018-04-30$2.0mus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2017-05-01 to 2018-04-30−$7.0mus-gaap:OperatingIncomeLoss
Interest expense12 months2017-05-01 to 2018-04-30$0us-gaap:InterestExpense
Income tax12 months2017-05-01 to 2018-04-30$0us-gaap:IncomeTaxExpenseBenefit
Net income12 months2017-05-01 to 2018-04-30−$6.8mus-gaap:NetIncomeLoss
Diluted EPS12 months2017-05-01 to 2018-04-30−$0.01us-gaap:EarningsPerShareBasicAndDiluted
Diluted shares (weighted)12 months2017-05-01 to 2018-04-30968,641,686 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow12 months2017-05-01 to 2018-04-30−$5.1mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2018-04-30$1.1mus-gaap:Cash
Current assetsAt period end2018-04-30$1.3mus-gaap:AssetsCurrent
Total assetsAt period end2018-04-30$6.4mus-gaap:Assets
Current liabilitiesAt period end2018-04-30$644.2kus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2018-04-30$644.2kus-gaap:Liabilities
Shareholders' equityAt period end2018-04-30$5.8mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001683168-18-001994. Last ingested by Listed: Nov 14, 2026, 20:52 ET. Listed shows no prices and gives no investment advice.